- Ali Yaghi. - Sara Yaghi. - Alia Shatnawi. 1 P a g e

Size: px
Start display at page:

Download "- Ali Yaghi. - Sara Yaghi. - Alia Shatnawi. 1 P a g e"

Transcription

1 -2 - Ali Yaghi - Sara Yaghi - Alia Shatnawi 1 P a g e

2 We ended the previous lecture with H2 receptor antagonists, which work by selectively inhibiting H2 receptors. They are widely used to treat: 1- GERD, but here PPI are more preferred because of their superior action and higher efficacy. 2- Non ulcer dyspepsia. 3- Stress related gastritis, can prevent bleeding, usually given IV. 4- Peptic ulcer disease, but H2 receptor antagonists become ineffective if: A) H. Pylori is the causative agent, in this case PPI are used. B) If NSAID is continued. Note: NSAIDS inhibit COX and decrease the prostaglandins, so we lose the protective action of the prostaglandins over the stomach. So they can cause peptic ulcer. We can only use H2 inhibitors if the patient stops taking NSAIDS. If the patient can t stop taking NSAIDS, we use PPI. PPI with the continuation of NSAIDS have better ability to heal the ulcer caused by the NSAIDS. The father of H2 receptor antagonists is Cimetidine (Tagamet). H2 receptor antagonists side effects: Extremely safe drugs, but can (in 3% of patients) cause diarrhoea, headache, fatigue, myalgia and constipation. Cimetidine has a lot of side effects. It inhibits cytochrome p450. We know that the metabolism of the drugs causes deactivation of the drug. As example, if a person is using digoxin (a drug used for treating heart failure), and I give him cimetidine, cimetidine will inhibit CYP450, which leads to a longer activity time for digoxin (because digoxin is deactivated by CYP450, which is in this case is inhibited by cimetidine). << Digoxin has a narrow therapeutic index, which means if we prescribe a higher dose than permitted, or if we inhibit its deactivation, we reach toxicity level. <<We use newer drugs such as Ranitidine, which has less ability and affinity to bind with CYP450. So it has less inhibitory effect. << Other new drugs like Nizatidine and Famotidine have negligible biding affinity to CYP450, so they are considered safer with regard to drug-drug interaction. Cimetidine has antiandrogenic activity. People who take this drug have high level of estradiol especially in men. Because it causes loss of libido, erectile dysfunction, increases secretion of prolactin which causes gynecomastia (breast enlargement in male). Cimetidine causes CNS effects in elderly, such as excitation, confusion and agitation. 2 P a g e

3 Duration of action: The duration of action is 12 hours, so these drugs are given 2 times a day. They are given before meals, and they are mainly effective in decreasing acid secretion during night (nocturne), and somehow effective in daytime and meal stimulated acid secretion. HCL secretion can be affected by: 1) H2 receptors antagonists. (We have finished talking about them). 2) Muscarinic muscle antagonists, which are not used a lot because of their side effects. 3) Proton pump inhibitors (PPI), which directly inhibit acid secretion. Proton pump inhibitors mechanism of action: 1- Drug must be absorbed in small intestine and delivered to parietal cell through the blood. They do not work directly in the stomach like antacids, they need to be absorbed first. 2- Drug is protonated and trapped in acidic canaliculi of parietal cells. The drug that we take is a prodrug, (it has to be activated in order to do its function). PPI are weak bases and they are acid labile (destroyed easily by the acidic environment). To protect the PPI from destruction in the stomach (as they are taken orally), they are ENCAPSULATED BY MICROENCAPSULATION. Then after reaching the small intestine, PPI are disintegrated and they are absorbed to the blood stream, (They enter easily because they are lipophilic). 3- Trapping of protonated drug within the acidic canaliculi next to target enzyme. Once the PPI which are weak bases- are in the canaliculi-where HCL is secreted-, the PPI will be protonated (charged), therefore the drug will not be able to get out of the canaliculi. This is good because that s where we want the drug to work. 4- It is an irreversible inhibition. (Covalent bond with amino acid cystine in the protein of the pump). 5- Full inhibition with 2:1 ratio of (drug: enzyme). Note: In order to stop the action of the drug, the pump must be recycled by degrading it then synthesizing a new one. Therefore, restoring the highest action of the pump (diminishing the activity of the drug) needs long time, around 4-5 days, and the duration of action of the drug is 24h. 3 P a g e

4 Half-lives of these drugs are very short (the unbound drug will be degraded quickly). Notes: 1- PPI : given once a day (twice in case of severe illness). 2- H2 antagonist: twice a day. 3- Antacids: many times a day (its duration of action is 2 hours maximum). That s why PPI are better because they are stronger and they are taken only once daily. Some PPI's : Omeprazole (oral). Rabeprazole (oral). Lanzoprazole (oral and IV). Pantoprazole (oral and IV). Esmoprazole (oral and IV). Note: The Reason for naming these drugs (-prazoles) is because they are benzyemidazole. Rabeprazole and immediate release omeprazole have faster onsets of action. So it should be given one hour before meal (opposite of antacids which are given after meals). Have short half-lives but their effect lasts for 24 hours due to irreversible inhibition. Pharmacodynamics: Proton pump inhibitors inhibit both fasting and meal-stimulated acid secretion because they block the final common pathway of acid secretion (90-98% of 24-hour secretion). Notes: 1- H2 receptor antagonists are preferable for night time acid secretion. 2- Night time acid secretion can be caused by the indigestion of food. 3- PPI are preferable for other acidity causes (especially during the daytime). 4 P a g e

5 Clinical Uses for PPI: 1- Gastroesophageal Reflux (GERD): PPI are better than H2 receptor antagonist 2- Non ulcer Dyspepsia: (can happen after heavy meals): - Modest activity % more beneficial than a placebo. 3- Stress- Related Gastritis: - If a patient has nasogastric tube, we can give him Oral immediate- release omeprazole. - For patients without a nasoenteric tube, IV H2-antagonists are preferred because of their proven efficacy. 4- Gastrinoma and other Hypersecretory Conditions: - Usually high doses of omeprazole are used. Although omeprazole can induce gastrin release, it still has a good activity for inhibiting HCL release. 5- Peptic Ulcer Disease: - They heal more than 90% of cases within 4-6 weeks. Especially good for: A- H. pylori- associated ulcers: - PPI eradicate H. pylori by direct antimicrobial activity and by lowering MIC (minimum inhibitory concentration) of the antibiotics. Note: PPI are used in triple therapy (we will talk about this later in this sheet). B- NSAID-associated ulcers: -PPIs promote ulcer healing despite continued NSAID use. (Remember H2 antagonist in this sheet). -Also used to prevent ulcer complications of NSAIDs. C- Rebleeding peptic ulcer: -Oral or IV PPI administration. -High ph may enhance coagulation and platelet aggregation. 5 P a g e

6 Adverse Effects of PPIs: General side effects: - Diarrhoea, headache, abdominal pain, not teratogenic in animals, but not used in pregnancy. - Reduction of cyanocobalamine absorption. - Increased risk of GI and pulmonary infection. - Atrophic gastritis and intestinal metaplasia. - Chronic inflammation in gastric body - They increase serum gastrin level which can cause: Carcinoid tumours in rats. Hyperplasia of parietal cells (ECL cells). Increase proliferative rate of the colonic mucosa but without cancer development. Drug Interactions: - Some drugs needs gastric acidity to be absorbed, so PPIs may affect absorption of drugs (like digoxin and ketoconazole and vitamin b12 complex) due to decreased gastric acidity. - It is noted that people who are along term use of PPI have a decreased level of vitamin B12. The solution for that is giving vitamin B12 injections or changing the drug. - Omeprazole can inhibit metabolism of coumadine, diazepam and phenytoin. - Rabeprazole and pantoprazole have no significant interactions with other drugs. Note: Long term use of PPI increases the risk of a hip fracture. It can be due to reduced amount of Ca2+ dissolved in the stomach (because calcium needs high acidity to be absorbed) OR because they interference with the breakdown and rebuilding of bone by interfering with the acid production of osteoclasts. Beware of using these drugs with osteoporotic patients. That s it for PPI. Muscarinic antagonists Atropine Pirenzepine 6 P a g e

7 Side effcets: urinary retention xerostomia blurred vision Now we will talk about Mucosal Protective Agents GI mucosal defence mechanisms: 1- Mucus secretion. 2- Cell-cell tight junctions (Restrict back diffusion of acid and pepsin). 3- Epithelial bicarbonate secretion. 4- Restitution: migration of some gland neck cells seals small erosions to re-establish intact epithelium. 5- Mucosal prostaglandins: Stimulate mucus and bicarbonate secretion. DRUGS that enhance mucosal protection 1.Sucralfate 2.Prostaglandin analogs (misoprostol, cytotec) 3.Bismuth compounds 1. Sucralfate: Is a salt of sucrose complexed to sulphated aluminium hydroxide. Has a negatively charged sucrose sulphate, which binds to positively charged proteins in the base of ulcer or erosions, forming a physical barrier that restricts further caustic damage and stimulates prostaglandin and bicarbonate secretion. In the stomach, it forms a viscous, tenacious paste that binds selectively to ulcers or erosions for up to 6 hours. Clinical Use: - 1 gm, four times daily on an empty stomach. - Reduces the incidence of GI bleeding in critically ill patients. - Acid inhibitory therapies may increase the risk of nosocomial pneumonia. 7 P a g e

8 Adverse Effects: It is not absorbed, so devoid of toxicity. Constipation in 2% of patients. Caution in renal insufficiency. Drug Interactions: May bind to other medications, thus impairing their absorption (wait 6 hours period). 2. Misoprostol: Prostaglandin analogue, a methyl analogue of PGE1. Half-life 30 minutes, so it s given 3-4 times daily. Stimulates mucus and bicarbonate secretion and enhances mucosal blood flow. Binds to prostaglandin receptor on the parietal cells, reducing the histaminestimulated camp production and causing modest acid inhibition. Also, stimulates electrolyte and fluid secretion, motility and uterine contractions. (Contraindicated with pregnancy because it causes abortion). Used in labour to facilitate delivery (Uterine rupture might occur). Mechanism of action: Misoprostol binds to prostaglandin receptor and reduces acidity, and enhance mucus and bicarbonate secretion. 8 P a g e

9 Which drug will target NSAID stimulated peptic ulcer pharmacologically? The answer is Misoprostol, because it will counteract the effect of NSAID. What is the best drug to treat NSAID stimulated peptic ulcer? The answer is PPI, because we do not like to use Misoprostol a lot because: A- It has a lot of side effects. B- Need for multiple daily dosing. C- PPI may be as effective and better tolerated. Note: Cyclooxygenase2-selective NSAIDs are an option for such patients. Side effects: 1- Can cause diarrhoea and abdominal cramping in 10-20% of patients. 2- Should not be used in pregnancy. 3. Colloidal Bismuth Compounds: 1- Bismuth subsalicylate. 2- Bismuth subcitrate. 3- Bismuth dinitrate. They coat the ulcers and make a protective layer inside the stomach, but they are additive. May stimulate prostaglandins, mucus and bicarbonate secretion. Bismuth subsalicylate inhibits intestinal prostaglandins and chloride secretion, so useful in infectious diarrhoea (travellers diarrhoea) leading to reduced liquidity and frequency of diarrhoea. Have direct antimicrobial effects and binds enterotoxins, so useful in travellers diarrhoea. Have direct activity against H. Pylori. Adverse effects: 1- Black stools and tongue. 2- Encephalopathy: headaches, ataxia, confusion and seizures. Note: they are not absorbed, but when they are absorbed, they cause the encephalopathy. 9 P a g e

10 Helicobacter pylori H pylori characteristics: 1- Helix-shaped Gram-negative bacterium. 2- Produces large amounts of the enzyme urease 3- It produces other enzymes including protease, vacuolating cytotoxin A (VacA), and certain phospholipases damage the mucosal epithelial cells. Note: The inflammatory response to the bacteria induces G cells in the antrum to secrete the hormone gastrin, which travels through the bloodstream to the fundus of stomach. Antibiotics to eradicate Helicobacter pylori: Clarithromycin Amoxicillin Metronidazole Tetracycline Clarithromycin-based triple therapy: PPI+ clarithromycin + amoxicillin or metronidazole for 14 days. (we give options because of the allergy to amoxicillin in some patients). Bismuth quadruple therapy (for penicillin allergic patients) : PPI or H2 Receptor antagonist + bismuth + metronidazole + tetracycline for days. GOOD LUCK 10 P a g e

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018 GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Z Gastroenterol. 1983 Mar;21 Suppl:111-6. [Effect of antacids on intestinal motility]. [Article in German] Wienbeck M, Erckenbrecht J, Strohmeyer G. Abstract

More information

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers

More information

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018 GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Drugs Used in Gastrointestinal Diseases Drugs used in Peptic Ulcer Diseases. Drugs Stimulating Gastrointestinal Motility &Laxatives. Antidiarrheal Agents. Drugs

More information

-Mohammad Ashraf. -Anas Raed. -Alia Shatnawi. 1 P a g e

-Mohammad Ashraf. -Anas Raed. -Alia Shatnawi. 1 P a g e -1 -Mohammad Ashraf -Anas Raed -Alia Shatnawi 1 P a g e Dr. Alia started the lecture by talking about subjects we are going to cover through this course; you can refer to the record if you are interested.

More information

Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases

Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases p1009 DRUGS USED IN ACID-PEPTIC DISEASES 1. classification of drugs 2. agents that reduce intragastric acidity Antacids,H 2 antagonists,proton

More information

A. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer.

A. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer. Pharmacology - Problem Drill 21: Drugs Used To Treat GI Disorders No. 1 of 10 1. Endogenous secretagogues for stomach acid include: #01 (A) Histamine (B) Gastrin (C) PGE1 (D) A and B (E) A, B and C Histamine

More information

Gastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D

Gastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:

More information

Second term/

Second term/ Second term/ 2015-2016 L. 1 Dr Mohammed AL-Zobaidy Learning objectives GIT pharmacology After completing this chapter the student will be able to: Recognise pathophysiological factors implicated in acid-peptic

More information

Peptic ulcer disease Disorders of the esophagus

Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth

More information

Case 4: Peptic Ulcer Disease. Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie

Case 4: Peptic Ulcer Disease. Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie Case 4: Peptic Ulcer Disease Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie Case 4: PUD Problem List: 1. Peptic Ulcer Disease SOAP Note: S Patient is complaining of abdominal pain

More information

Copy right protected Page 1

Copy right protected Page 1 DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.

More information

OSPAP Programme. Gastrointestinal Drugs. Dr. Adrian Moore Dale

OSPAP Programme. Gastrointestinal Drugs. Dr. Adrian Moore Dale PAP Programme Dr. Adrian Moore Dale 1.03 Adrian.Moore@sunderland.ac.uk 0191 5152554 lide 1 of 26 PAP MPM14 Acid-Related Pathophysiology The stomach secretes: ydrochloric acid (Cl) aids digestion and also

More information

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory

More information

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both

More information

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011 KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology

More information

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35. An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology

More information

Drugs Affecting the Gastrointestinal System. Antacids, Constipation, Increasing gastrointestinal motility

Drugs Affecting the Gastrointestinal System. Antacids, Constipation, Increasing gastrointestinal motility Drugs Affecting the Gastrointestinal System Antacids, Constipation, Increasing gastrointestinal motility Cells of the Gastric Gland parietal cells: produce & secrete HCl primary site of action for many

More information

Lab:2 Drugs acting on Gastrointestinal tract

Lab:2 Drugs acting on Gastrointestinal tract Lab:2 Drugs acting on Gastrointestinal tract Drugs that used to treat three common medical conditions involving the gastrointestinal tract: peptic ulcers and gastroesophageal reflux disease (GERD), chemotherapy-induced

More information

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials. Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs

More information

Pharmacology. Drugs that Affect the Gastrointestinal System

Pharmacology. Drugs that Affect the Gastrointestinal System Pharmacology Drugs that Affect the Gastrointestinal System Topics Peptic Ulcer Disease Constipation Diarrhea Emesis Digestion Peptic Ulcer Disease Factors that Increase Acidity Factors that Protect Against

More information

PHARMACOLOGY OF GASTROINTESTINAL TRACT TREATMENT OF ULCER DISEASE

PHARMACOLOGY OF GASTROINTESTINAL TRACT TREATMENT OF ULCER DISEASE PHARMACOLOGY OF GASTROINTESTINAL TRACT TREATMENT OF ULCER DISEASE Definition A circumscribed ulceration of the gastrointestinal mucosa occurring in areas exposed to acid and pepsin and most often caused

More information

Module 2 Heartburn Glossary

Module 2 Heartburn Glossary Absorption Antacids Antibiotic Module 2 Heartburn Glossary Barrett s oesophagus Bloating Body mass index Burping Chief cells Colon Digestion Endoscopy Enteroendocrine cells Epiglottis Epithelium Absorption

More information

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Proton Pump Inhibitors Drug Class Prior Authorization Protocol Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review

More information

National Digestive Diseases Information Clearinghouse

National Digestive Diseases Information Clearinghouse Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach

More information

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority

More information

Peptic ulcer disease 1 GIT. Dr Kawa Ahmad PhD Pharmaceutics

Peptic ulcer disease 1 GIT. Dr Kawa Ahmad PhD Pharmaceutics 51 Peptic ulcer disease Dr Kawa Ahmad PhD Pharmaceutics 1 GIT Food taken into the mouth is mixed with saliva to form a plastic mass. The salivary glands secrete about 1 L of fluid daily; this contains

More information

Reflux of gastric contents, particularly acid, into the esophagus

Reflux of gastric contents, particularly acid, into the esophagus Heartburn Reflux of gastric contents, particularly acid, into the esophagus Patient assessment with GERD 1-signs and symptoms The hallmark of typical symptom of GERD is heartburn (restrosternal),acid regurgitation,

More information

Heartburn, also referred to acid reflux, happens when stomach acid flows back (refluxes) into your esophagus.

Heartburn, also referred to acid reflux, happens when stomach acid flows back (refluxes) into your esophagus. WHILE almost everyone experiences mild heartburn from time to time and many individuals have some antacids or another medication on hand for its relief, talk to your doctor, if you have heartburn more

More information

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet

More information

Diarrhea. Omeprazole and Sodium Bicarbonate may increase your risk of getting severe diarrhea. This

Diarrhea. Omeprazole and Sodium Bicarbonate may increase your risk of getting severe diarrhea. This Medication Guide Omeprazole and Sodium Bicarbonate Powder for Oral Suspension and Capsules Read this Medication Guide before you start taking Omeprazole and Sodium Bicarbonate and each time you get a refill.

More information

Gastrointestinal Pharmacology

Gastrointestinal Pharmacology Gastrointestinal Pharmacology Jan Kehr Department of Physiology and Pharmacology Gastrointestinal Pharmacology v Background v Peptic disorders v Constipation and Diarrhea v Chronic Bowel Disease Gastrointestinal

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,

More information

Esomeprazole strontium can have other serious side effects. See What are the possible side effects of esomeprazole strontium?

Esomeprazole strontium can have other serious side effects. See What are the possible side effects of esomeprazole strontium? MEDICATION GUIDE ESOMEPRAZOLE STRONTIUM (es-o-mep-ra-zol stron-tee-um) delayed-release capsules Read the Medication Guide that comes with esomeprazole strontium before you start taking esomeprazole strontium

More information

PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School

PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease

More information

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia

More information

Pthaigastro.org. Evolution of antisecretory agents. History. Antacids and anticholinergic drugs

Pthaigastro.org. Evolution of antisecretory agents. History. Antacids and anticholinergic drugs Evolution of antisecretory agents uthapong Ukarapol, MD. Division of Gastroenterology Chiang Mai University istory 1823- Prout discovered gastric hydrochloric acid 1875- eidenhain and 1893- Golgi identified

More information

Overview of digestion or, gut reactions - to food

Overview of digestion or, gut reactions - to food Key concepts in Digestion. Indigestion module Overview of digestion or, gut reactions - to food Prof. Barry Campbell Gastroenterology Cellular & Molecular Physiology e-mail: bjcampbl@liv.ac.uk http://pcwww.liv.ac.uk/~bjcampbl

More information

Overview of digestion or, gut reactions - to food

Overview of digestion or, gut reactions - to food 1 Key concepts in Digestion. Indigestion module Overview of digestion or, gut reactions to food Prof. Barry Campbell Gastroenterology Cellular & Molecular Physiology email: bjcampbl@liv.ac.uk http://pcwww.liv.ac.uk/~bjcampbl

More information

UPPER GI DISEASES 11/15/2014. Lesson Objectives. GI Tract Review. NUTR 2050 Nutrition for Nursing Professionals. Mrs. Deborah A. Hutcheon, MS, RD, LD

UPPER GI DISEASES 11/15/2014. Lesson Objectives. GI Tract Review. NUTR 2050 Nutrition for Nursing Professionals. Mrs. Deborah A. Hutcheon, MS, RD, LD UPPER GI DISEASES NUTR 2050 Nutrition for Nursing Professionals Mrs. Deborah A. Hutcheon, MS, RD, LD Lesson Objectives At the end of the lesson, the student will be able to: 1. Describe causes and contributing

More information

Management of Dyspepsia

Management of Dyspepsia MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively

More information

All pharmacodynamic effects observed can be explained by the effect of omeprazole on acid secretion.

All pharmacodynamic effects observed can be explained by the effect of omeprazole on acid secretion. OMEPRAZOLE Losec 10mg and 20mg Capsules Acid Pump Inhibitors FORMULATION Each capsule contains Omeprazole 10 mg or 20 mg. PHARMACEUTICAL FORM Omeprazole (LOSEC) capsule 10 mg: hard gelatin capsule with

More information

Helicobacter pylori:an Emerging Pathogen

Helicobacter pylori:an Emerging Pathogen Bacteriology at UW-Madison Bacteriology 330 Home Page Helicobacter pylori:an Emerging Pathogen by Karrie Holston, Department of Bacteriology University of Wisconsin-Madison Description of Helicobacter

More information

August 2003 Peptic Ulcer Management H01

August 2003 Peptic Ulcer Management H01 W-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL 60015 847-945-8050 August 2003 Peptic Ulcer Management 707-000-03-008-H01 MISSING A LESSON? IT S EASY TO GO TO OUR WEBSITE &

More information

Optimal Drugs for ICU Stress Ulcer Prophylaxis: Other. Grand Rounds Monday August 9, 2010 Teresa Jones R2

Optimal Drugs for ICU Stress Ulcer Prophylaxis: Other. Grand Rounds Monday August 9, 2010 Teresa Jones R2 Optimal Drugs for ICU Stress Ulcer Prophylaxis: Other Grand Rounds Monday August 9, 2010 Teresa Jones R2 Outline Options besides PPIs Comparison to PPIs Negative Effects of PPIs Conclusion Do we really

More information

Understandings, Applications & Skills

Understandings, Applications & Skills D.2 Digestion Understandings, Applications & Skills Statement D.2.U1 Nervous and hormonal mechanisms control the secretion of digestive juices. D.2.U2 Exocrine glands secrete to the surface of the body

More information

Safety Of. long-term PPI. Layli Eslami, MD Tehran, 1393

Safety Of. long-term PPI. Layli Eslami, MD Tehran, 1393 Safety Of long-term PPI Layli Eslami, MD Tehran, 1393 n The introduction of PPIs in the late 1980s optimized the medical treatment of acidrelated disorders n In some cases such as GERD patients given the

More information

MEDICATION GUIDE. Rabeprazole Sodium Delayed-Release Tablets Rx Only

MEDICATION GUIDE. Rabeprazole Sodium Delayed-Release Tablets Rx Only MEDICATION GUIDE Rabeprazole Sodium Delayed-Release Tablets Rx Only Read the Medication Guide that comes with rabeprazole sodium delayed-release tablets before you start taking it and each time you get

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT "Carbellon" Tablets. 2. Qualitative and Quantitative Composition Active Constituents: Activated Charcoal Ph.Eur. Magnesium Hydroxide Ph.Eur.

More information

Treatment of Helicobacter pylori Infection

Treatment of Helicobacter pylori Infection Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk

More information

MEDICATION GUIDE Lansoprazole Delayed-Release Capsules, USP

MEDICATION GUIDE Lansoprazole Delayed-Release Capsules, USP MEDICATION GUIDE Lansoprazole Delayed-Release Capsules, USP Read this Medication Guide before you start taking lansoprazole delayed-release capsules and each time you get a refill. There may be new information.

More information

Policy Evaluation: Proton Pump Inhibitors (PPIs)

Policy Evaluation: Proton Pump Inhibitors (PPIs) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Week 12 - Outline. Outline. Digestive System I Major Organs. Overview of Digestive System

Week 12 - Outline. Outline. Digestive System I Major Organs. Overview of Digestive System Outline Week 12 - Digestive System I Major Organs Copyright The McGraw-Hill Companies, Inc. Permission required for reproduction or display. Digestive Tract Function GI Tract Structure Regulation of the

More information

Peptic Ulcer Disease Update

Peptic Ulcer Disease Update Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following

More information

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Hp : Helicobacter pylori Part 1. Pathophysiology and immune response Pathogenesis of Hp infection Part 2. Clinical manifestation Part 3. Dx tests for

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. lansoprazole delayed-release capsule (Manufacturer s standard)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. lansoprazole delayed-release capsule (Manufacturer s standard) READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr PREVACID lansoprazole delayed-release capsule (Manufacturer s standard) Read this carefully before you start taking

More information

Digestive System. - Food is ingested

Digestive System. - Food is ingested 11 V. Digestive Processes in the Mouth - Food is ingested - Mechanical digestion begins (chewing) - Salivary amylase begins chemical breakdown of starch - Propulsion is initiated by Deglutition (Swallowing)

More information

Management of dyspepsia and of Helicobacter pylori infection

Management of dyspepsia and of Helicobacter pylori infection Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia

More information

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division

More information

Sequioa Education Systems, Inc. 1

Sequioa Education Systems, Inc.  1 Functional Diagnostic Medicine Training Program Module 2 The Functional Diagnostic Medicine Approach in the Treatment of Gastrointestinal Dysfunction and Disease Dr. Wayne L. Sodano, D.C., D.A.B.C.I. &

More information

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb

More information

Update on the pathological classification of gastritis. Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada

Update on the pathological classification of gastritis. Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada Update on the pathological classification of gastritis Hala El-Zimaity, M.D. M.S. Epidemiology McMaster University Hamilton, Ontario Canada CLASSIFICATION GASTRITIS GASTROPATHY 1. Acute 2. Chronic 3. Uncommon

More information

Gastric ulcer: The recommended dosage is Pepzol 20 mg once daily. Symptom resolution is rapid and in most

Gastric ulcer: The recommended dosage is Pepzol 20 mg once daily. Symptom resolution is rapid and in most Name Pepzol (Omeprazole) 20 mg, 40 mg Modified release (MR) Capsules Composition Each capsule Contains: Omeprazole 20 mg or 40 mg For excipients see "list of excipients" Pharmaceutical form Pepzol capsules

More information

SELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY

SELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)

More information

Digestion. Absorption and Transport. Digestion. Digestion. (Chapter 3) Your GI tract is like a tube!

Digestion. Absorption and Transport. Digestion. Digestion. (Chapter 3) Your GI tract is like a tube! Digestion Absorption and Transport Digestion the process of breaking down food into its basic components so they can be absorbed CHO, fat, pro are hydrolysed Vits, mins, water aren t (Chapter 3) Digestion

More information

MEDICATION GUIDE. PREVACID can have other serious side effects. See What are the possible side effects of PREVACID?

MEDICATION GUIDE. PREVACID can have other serious side effects. See What are the possible side effects of PREVACID? Page 33 of 39 MEDICATION GUIDE PREVACID (prev-a-sid) (lansoprazole) Delayed-Release Capsules and PREVACID SoluTab (prev-a-sid sol-u-tab) (lansoprazole) Delayed-Release Orally Disintegrating Tablets Read

More information

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection

More information

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment

More information

Esomeprazole Magnesium Delayed-Release Capsules, USP

Esomeprazole Magnesium Delayed-Release Capsules, USP Esomeprazole Magnesium Delayed-Release Capsules, USP (es" oh mep' ra zole mag nee' zee um) Read the Medication Guide that comes with esomeprazole magnesium delayed-release capsules before you start taking

More information

* Adults. NSAID associated peptic ulceration: - Acute treatment: 150 mg twice daily for 8 to 12 weeks, or 300mg nocte.

* Adults. NSAID associated peptic ulceration: - Acute treatment: 150 mg twice daily for 8 to 12 weeks, or 300mg nocte. Trade Name Aciloc 75 mg & 300 mg Film-coated tablets Generic Name Ranitidine Composition Each Aciloc 300 mg film-coated tablet contains: - Active ingredient: Ranitidine hydrochloride 336 mg equivalent

More information

EU RISK MANAGEMENT PLAN (EU RMP)

EU RISK MANAGEMENT PLAN (EU RMP) EU RISK MANAGEMENT PLAN (EU RMP) Active substance(s) (INN or common name): Esomeprazole Pharmaco-therapeutic group (ATC Code): A02B C05 Name of Marketing Authorisation Holder or Applicant: Strength and

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,

More information

Fecal incontinence causes 196 epidemiology 8 treatment 196

Fecal incontinence causes 196 epidemiology 8 treatment 196 Subject Index Achalasia course 93 differential diagnosis 93 esophageal dysphagia 92 95 etiology 92, 93 treatment 93 95 work-up 93 Aminosalicylates, pharmacokinetics and aging effects 36 Antibiotics diarrhea

More information

HELICOBACTER PYLORI UPDATE

HELICOBACTER PYLORI UPDATE HELICOBACTER PYLORI UPDATE PROF. TAWHEED MOWAFY DEAN OF AZAL FACULTY OF MEDICINE INTRODUCTION (H. pylori) is recognised as the most common chronic human bacterial infection,1 affecting up to 50% of the

More information

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors

More information

CAS (rabeprazole) CAS (rabeprazole sodium)

CAS (rabeprazole) CAS (rabeprazole sodium) Parbezol Tablets PRODUCT INFORMATION NAME OF THE MEDICINE Rabeprazole sodium CAS-117976-89-3 (rabeprazole) CAS-117976-90-6 (rabeprazole sodium) The chemical name for rabeprazole sodium is (±) 2-[{4-(3-methoxypropoxy)-3-

More information

Medication Guide. Omeprazole and Sodium Bicarbonate Capsules (oh mep ra zole and soe dee um bye kar bo nate)

Medication Guide. Omeprazole and Sodium Bicarbonate Capsules (oh mep ra zole and soe dee um bye kar bo nate) Medication Guide Omeprazole and Sodium Bicarbonate Capsules (oh mep ra zole and soe dee um bye kar bo nate) Read this Medication Guide before you start taking omeprazole and sodium bicarbonate capsules

More information

NAME OF THE MEDICINAL PRODUCT

NAME OF THE MEDICINAL PRODUCT PARIET Janssen NAME OF THE MEDICINAL PRODUCT PARIET (rabeprazole sodium) QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: 9.42 mg rabeprazole as 10 mg rabeprazole sodium or 18.85 mg rabeprazole

More information

MY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT?

MY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT? MY PATIENT HAS READ THAT HIS PPI S MAY BE TROUBLE. NOW WHAT? Clarence Wong MD FRCPC Associate Professor FACULTY/PRESENTER DISCLOSURE Faculty: Clarence Wong Relationships with commercial interests: Grants/Research

More information

5. Which component of the duodenal contents entering the stomach causes the most severe changes to gastric mucosa:

5. Which component of the duodenal contents entering the stomach causes the most severe changes to gastric mucosa: Gastro-intestinal disorders 1. Which are the most common causes of chronic gastritis? 1. Toxic substances 2. Chronic stress 3. Alimentary factors 4. Endogenous noxious stimuli 5. Genetic factors 2. Chronic

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. OMEPRAZOLE Omeprazole Delayed-Release Capsules

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. OMEPRAZOLE Omeprazole Delayed-Release Capsules READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr OMEPRAZOLE Omeprazole Delayed-Release Capsules Read this carefully before you start taking OMEPRAZOLE and each time

More information

INFORMATION FOR THE CONSUMER

INFORMATION FOR THE CONSUMER INFORMATION FOR THE CONSUMER IMPORTANT INFORMATION YOU SHOULD KNOW ABOUT NAT-Omeprazole DR (omeprazole magnesium delayed release tablets) Read this leaflet carefully. It contains general points about NAT-Omeprazole

More information

Prevpac Pylera Omeclamox-Pak

Prevpac Pylera Omeclamox-Pak Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,

More information

Medication Guide Lansoprazole Delayed-Release Capsules, USP (lanz-ah-pray-zol)

Medication Guide Lansoprazole Delayed-Release Capsules, USP (lanz-ah-pray-zol) Medication Guide Lansoprazole Delayed-Release Capsules, USP (lanz-ah-pray-zol) Read this Medication Guide before you start taking lansoprazole delayed-release capsules and each time you get a refill. There

More information

PACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent

PACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) PARIET 10 mg tablets PARIET 20 mg tablets COMPOSITION 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole

More information

SUCRALFATE TABLETS, USP

SUCRALFATE TABLETS, USP 1234567890 10 210002 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:

More information

What Is Peptic Ulcer Disease?

What Is Peptic Ulcer Disease? What Is Peptic Ulcer Disease? Peptic ulcer disease is when painful sores form in the lining of the stomach, duodenum (start of the small intestine) or bowels. An ulcer can cause belly pain and, in some

More information

Peptic Ulcer Disease and NSAIDs

Peptic Ulcer Disease and NSAIDs Peptic Ulcer Disease and NSAIDs National Digestive Diseases Information Clearinghouse What is a peptic ulcer? A peptic ulcer is a sore on the inner lining of the stomach or duodenum the first part of the

More information

Exam Key. NROSCI/BIOSC 1070 and MSNBIO 2070 Final Exam December 19, 2015 Total POINTS: % of grade in class

Exam Key. NROSCI/BIOSC 1070 and MSNBIO 2070 Final Exam December 19, 2015 Total POINTS: % of grade in class NROSCI/BIOSC 1070 and MSNBIO 2070 Final Exam December 19, 2015 Total POINTS: 100 20% of grade in class 1) Zollinger-Ellison syndrome results from a gastrin-secreting tumor, producing increased numbers

More information

Peptic Ulcer Disease: Zollinger-Ellison Syndrome

Peptic Ulcer Disease: Zollinger-Ellison Syndrome GASTROINTESTINAL PHYSIOLOGY 235 Case 41 Peptic Ulcer Disease: Zollinger-Ellison Syndrome Abe Rosenfeld, who is 47 years old, owns a house painting business with his brothers. The brothers pride themselves

More information

Gastritis General standpoints

Gastritis General standpoints Gastritis General standpoints Histologically documented inflammation ~60% in mucosal biopsy specimens. Heterogeneous etiology. More than 100 classification system. Classified based on time course (acute

More information

Digestive System Module 4: The Stomach *

Digestive System Module 4: The Stomach * OpenStax-CNX module: m49286 1 Digestive System Module 4: The * Donna Browne Based on The by OpenStax This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 4.0

More information

Ranitidine hydrochloride syrup containing 150mg Ranitidine per 10mL

Ranitidine hydrochloride syrup containing 150mg Ranitidine per 10mL Peptisoothe Ranitidine hydrochloride syrup containing 150mg Ranitidine per 10mL Presentation PEPTISOOTHE is a clear to pale yellow syrup with a spearmint flavour. Each 10mL of the syrup contains ranitidine

More information

Proton Pump Inhibitors. Description

Proton Pump Inhibitors. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors

More information

SUCRALFATE TABLETS, USP

SUCRALFATE TABLETS, USP 1234567890 10 210002-01 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:

More information

ulcer healing role 118 Bicarbonate, prostaglandins in duodenal cytoprotection 235, 236

ulcer healing role 118 Bicarbonate, prostaglandins in duodenal cytoprotection 235, 236 Subject Index Actin cellular forms 48, 49 epidermal growth factor, cytoskeletal change induction in mucosal repair 22, 23 wound repair 64, 65 polyamine effects on cytoskeleton 49 51 S-Adenosylmethionine

More information

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention

More information

Do You Know Your SATs? (Sugar, Acid blockers, Thinners) Laura Habighorst RN CAPA CGRN Heartland SGNA Spring Conference 2014

Do You Know Your SATs? (Sugar, Acid blockers, Thinners) Laura Habighorst RN CAPA CGRN Heartland SGNA Spring Conference 2014 Do You Know Your SATs? (Sugar, Acid blockers, Thinners) Laura Habighorst RN CAPA CGRN Heartland SGNA Spring Conference 2014 Objectives Describe the anesthesia contraindications for the administration of

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. OMEPRAZOLE Omeprazole Delayed-Release Capsules

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. OMEPRAZOLE Omeprazole Delayed-Release Capsules READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION OMEPRAZOLE Omeprazole Delayed-Release Capsules Read this carefully before you start taking OMEPRAZOLE and each time

More information

Dyspepsia. Dyspepsia covers upper abdominal pain, fullness, early satiety, bloating, and nausea.

Dyspepsia. Dyspepsia covers upper abdominal pain, fullness, early satiety, bloating, and nausea. Antacids Hawler medical university Collage of pharmacy/ fourth year /pharmacy practice Sham A. Talat Shareef (B.Sc. Msc. clinical pharmacy) 2017-2018 Sham_talat@yahoo.com Head of Department Of Clinical

More information